February 2019
- Medibio Extension of Entitlement Offering
- Medibio Investor Presentation
January 2019
- Medibio Results of January 2019 General Meeting
- Medibio Cleansing Notice and Appendix 3B
- Medibio Quarterly Update & Cash Flow
December 2018
- Medibio Requests Trading Halt
- Medibio Converting Note & Non-Renounceable Entitlement Offer
- Medibio Section 708AA(2)(F) Cleansing Statement and Appendix 3B
- Medibio Updated Investor Presentation December 10, 2018
- Medibio Notification of Pro-Rata Non-Renounceable Entitlement Issue
- Medibio Letter to Shareholders Entitlement Offer
- Medibio Letter to Ineligible Shareholders Entitlement Offer
- Medibio Rights Issue Offer Document
- Medibio Notice of General Meeting
- Medibio Announces Changes to the Board of Directors and Cost Reduction Plans
November 2018
- Medibio Market Update
- Medibio Appoints Global Healthcare & Medical Device Leader as CEO and Managing Director
- Medibio Provides Update on FDA Process
- Medibio Provides Chairman’s Address to Shareholders
- Medibio Announces Appointment of Joint Corporate Secretary
- Medibio Releases Results of Annual General Meeting
- Medibio Signs Insurance Company AIA Australia Ltd (AIAA) For an Exclusive Pilot Program For ilumen™
- Medibio Provides Updated Investor Deck
October 2018
- Notice Received Under Section 249D of the Corporations Act
- Medibio Releases Corporate Health Product, ilumen™
- Medibio Updates Company Presentation
- Medibio Technology Honored with Two Presentations at Mayo Clinic Convergence Neuroscience 2018
- Medibio Receives R&D Tax Incentive Refund
- Medibio Notice of Annual General Meeting
- Medibio Signs ilumen™ Corporate Contract with a Large Australian Employer
- Medibio Quarterly & Cash Flow Report
September 2018
-
Medibio Clinical Study Shows Over 20% Improvement to Current Diagnostic Standard
- Medibio Hosts Call to Discuss Clinical Validation Study
- Medibio Market Update
- Medibio Releases Appendix 4G & Corporate Governance Statement
- Medibio Releases Financial Report for the Year Ended 30 June 2018
- Medibio Announces Executive Leadership Changes
August 2018
-
Medibio announces change in senior management
July 2018
-
Medibio Submits FDA De Novo Application
- Medibio to announce fourth quarter FY18 results
- Quarterly Update and Message from CEO of Medibio Limited
June 2018
-
Appointment and Resignation of Company Secretary And Change of Registered Office Address
- Medibio provides updated Investor Presentation
- Medibio to Provide Corporate Health Investor Presentation
- Medibio Receives TGA Approval
- Peer-reviewed Neurology Publication on Medibio Science
May 2018
- Medibio Announces Global Launch – Corporate Mental Health For Business
- Medibio Receives CE Certification
- Medibio Corporate Health contract signed with Australia’s 3rd largest private healthcare provider
- Medibio Launches Personal Mental Health Measurement App for Apple Watch
- Medibio Announces Next Tranche of Corporate Health Contracts
- Medibio Corporate Health Signs Global Contract with Jacobs Engineering
April 2018
- Medibio finalizes acquisition of Vital Conversations
- Medibio Announces Scientific Advisory Board
- Medibio to announce third Quarter FY18 update and cashflow
- Quarterly ASX Update and Cashflows
January 2018
-
Peter Carlisle Appointed as Director
- Medibio Investor Conference Call Announcement
- Australia – 1st February
- U.S. – January 31st
December 2017
-
U.S. Department of Veterans Affairs White River Junction Medical Center Joins Medibio Depression Diagnostic Confirmatory Study to Support FDA Clearance
-
Mayo Clinic to begin Prospective Clinical Study with Medibio Technology for Expanded Market Opportunities
November 2017
June 2017
April 2017
March 2017
October 2016
- App 3B (7 Oct 2016)
- Funding Update (10 Oct 16)
- MEB Annual 2016 (10 Oct 2016)
- Partners with HBF and Vital Conversation (11 Oct 2016)
- MEB R & D Tax Incentive Refund
- Notice of Annual General Meeting (28 Oct 2016)
- Medibio Shareholder Newsletter (28 Oct 2016)
- App 3B (28 Oct 2016)
- Quarterly report (31 Oct 2016)
- Quarterly Cash Flow Report (30 Oct 2016)
July 2016
May 2016
January 2016
November 2015
- MEB Quarterly Report for the period ending (30 Sep 2015)
- MEB’s Signs First Multinational Client (6 Nov 2015)
- MEB Foster Research Report (10 Nov 2015)
- MEB ASX Investor Series Presentation (17 Nov 2015)
- MEB Final JHU Release-IRB (ASX Release) (24 Nov 2015)
- MEB Corporate Wellness Partner Program Commences (26 Nov 2015)
June 2015
April 2015
- Medibio Investor Presentation (April 2015)
- Completion of Restructure (2 April 2015)
- Distinguished Clinician Dr Frank Prendergast joins MEB (12 April 2015)
- U.S. Patent (21 April 2015)
December 2014
October 2014
Archived Announcements
November
Frontier Oil Corporation Shareholder Update
Appendix 3Z Director Final Interest
Appendix 3X Director Initial Interest
Appointments of New Director & Chairman
Results of Annual General Meeting
October
Frontier Oil Corporation IPO Approval
Notice of Annual General Meeting/Proxy Form
September
Convertible Note Restructure Clarification
August
July
April
Corporate Governance Policy Update
February
Half-Yearly Report to 31 December 2013
Update on Frontier Oil Investment